| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
WAY-299562 specifically modulates the interaction between protein kinase A (PKA) and A-kinase anchoring proteins (AKAP). By regulating this protein-protein interaction, the compound affects the subcellular localization and compartmentalization of PKA activity, thereby modulating cAMP-dependent signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, WAY-299562 modulates the PKA-AKAP interaction. By regulating this protein-protein interaction, the compound can affect PKA activity and downstream signaling. Specific biochemical and cellular activity data is limited in publicly available sources.
|
| ln Vivo |
In vivo activity of WAY-299562 has been investigated in preclinical models. By modulating PKA-AKAP interactions, the compound may affect cAMP-dependent signaling and produce physiological or therapeutic effects. Specific in vivo efficacy data is limited, as the compound is primarily used as a research tool.
|
| Enzyme Assay |
The modulation of PKA-AKAP interactions by WAY-299562 is typically assessed using biochemical assays such as surface plasmon resonance (SPR) or fluorescence polarization (FP). Recombinant PKA regulatory subunits and AKAP peptides are used to measure the binding affinity in the presence of varying concentrations of the compound. Competition assays can determine the compound's ability to disrupt or stabilize the PKA-AKAP interaction.
|
| Cell Assay |
Cellular assays for WAY-299562 involve treating cells with the compound and assessing PKA activity and localization. PKA activity is measured using kinase activity assays with specific substrates. The subcellular localization of PKA is assessed by immunofluorescence using anti-PKA antibodies. AKAP-dependent signaling pathways are evaluated by measuring the phosphorylation of PKA substrates.
|
| Animal Protocol |
In vivo studies of WAY-299562 are conducted in rodent models of diseases where PKA-AKAP interactions are implicated. The compound is administered via intraperitoneal (i.p.) injection or oral gavage. Tissue samples are collected for analysis of PKA activity, substrate phosphorylation, and pathway modulation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of WAY-299562 are evaluated in rodents following administration. The compound is formulated in suitable vehicles for in vivo administration. Plasma concentrations are measured using LC-MS/MS to determine key PK parameters including oral bioavailability and half-life.
|
| Toxicity/Toxicokinetics |
WAY-299562 is intended for research use only and is not approved for clinical use. Standard toxicology assessments would include acute and repeat-dose toxicity studies in rodents. No specific toxicity data is available in the public domain for this compound.
|
| Additional Infomation |
WAY-299562 is a research tool for studying the role of PKA-AKAP interactions in cellular signaling. PKA is a key mediator of cAMP signaling, and AKAPs are scaffolding proteins that direct PKA to specific cellular locations, ensuring spatial and temporal control of PKA activity. Disrupting PKA-AKAP interactions can have profound effects on cellular signaling and has been implicated in various diseases including cancer, cardiac disease, and neurological disorders.
|
| Molecular Formula |
C16H13NO3
|
|---|---|
| Molecular Weight |
267.279
|
| Exact Mass |
267.09
|
| Elemental Analysis |
C, 71.90; H, 4.90; N, 5.24; O, 17.96
|
| CAS # |
299934-88-6
|
| PubChem CID |
5400671
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
455
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC(=CC=C1)C2=N/C(=C\C3=CC=C(O3)C)/C(=O)O2
|
| InChi Key |
IXVNOOZSQRQBDU-ZROIWOOFSA-N
|
| InChi Code |
InChI=1S/C16H13NO3/c1-10-4-3-5-12(8-10)15-17-14(16(18)20-15)9-13-7-6-11(2)19-13/h3-9H,1-2H3/b14-9-
|
| Chemical Name |
(Z)-4-((5-methylfuran-2-yl)methylene)-2-(m-tolyl)oxazol-5(4H)-one
|
| Synonyms |
WAY-299562; WAY299562; WAY 299562
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7414 mL | 18.7070 mL | 37.4139 mL | |
| 5 mM | 0.7483 mL | 3.7414 mL | 7.4828 mL | |
| 10 mM | 0.3741 mL | 1.8707 mL | 3.7414 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
